Gulf International Bank UK Ltd Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Gulf International Bank UK Ltd has reduced its stake in Regeneron Pharmaceuticals by 24.9%, selling 2,097 shares in the first quarter, leaving them with 6,327 shares valued at approximately $4 million.
• Regeneron Pharmaceuticals reported $12.89 earnings per share for the last quarter, far exceeding analysts' consensus estimate of $8.43, contributing to a revenue increase of 3.6% year-over-year.
• The company has announced a quarterly dividend of $0.88 per share, reflecting an annualized dividend yield of 0.6% and will be paid to shareholders on September 3rd.

Gulf International Bank UK Ltd lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 24.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,327 shares of the biopharmaceutical company's stock after selling 2,097 shares during the period. Gulf International Bank UK Ltd's holdings in Regeneron Pharmaceuticals were worth $4,012,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. National Pension Service boosted its holdings in shares of Regeneron Pharmaceuticals by 8.9% during the 1st quarter. National Pension Service now owns 253,046 shares of the biopharmaceutical company's stock valued at $160,489,000 after buying an additional 20,596 shares in the last quarter. LGT Fund Management Co Ltd. raised its position in shares of Regeneron Pharmaceuticals by 17.5% in the 1st quarter. LGT Fund Management Co Ltd. now owns 658 shares of the biopharmaceutical company's stock worth $417,000 after purchasing an additional 98 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Regeneron Pharmaceuticals by 6.9% in the 1st quarter. Russell Investments Group Ltd. now owns 146,740 shares of the biopharmaceutical company's stock worth $93,079,000 after purchasing an additional 9,532 shares during the last quarter. Resona Asset Management Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 3.3% in the 1st quarter. Resona Asset Management Co. Ltd. now owns 38,436 shares of the biopharmaceutical company's stock worth $24,393,000 after purchasing an additional 1,225 shares during the last quarter. Finally, Callan Family Office LLC raised its position in shares of Regeneron Pharmaceuticals by 21.4% in the 1st quarter. Callan Family Office LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $1,208,000 after purchasing an additional 336 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $14.44 on Friday, hitting $580.41. 1,121,578 shares of the company traded hands, compared to its average volume of 985,857. The business's 50 day moving average price is $544.21 and its 200-day moving average price is $594.90. The company has a market capitalization of $61.52 billion, a price-to-earnings ratio of 14.63, a P/E/G ratio of 1.93 and a beta of 0.33. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the previous year, the firm earned $11.56 earnings per share. The company's revenue for the quarter was up 3.6% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on REGN shares. Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Citigroup reaffirmed a "buy" rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Morgan Stanley reaffirmed an "overweight" rating and issued a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Rothschild & Co Redburn initiated coverage on Regeneron Pharmaceuticals in a research report on Thursday. They issued a "buy" rating and a $890.00 price target for the company. Finally, Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price for the company. in a research report on Friday, August 1st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $838.00.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.